Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma

Journal of Gastrointestinal Oncology

Do Joong Park¹  David H. Ilson⁴  Valerie W. Rusch⁵  Brittanie Millang⁴  Karyn A. Goodman¹  Sam S. Yoon²  Marinela Capanu³  Nabil P. Rizk¹  Geoffrey Y. Ku⁴  Manjit S. Bains⁵  Yelena Y. Janjigian⁴ 

[1] Gastric and Mixed Tumor Service,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USAGastric and Mixed Tumor Service,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USAGastric and Mixed Tumor Service,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA;Department of Epidemiology/Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USADepartment of Epidemiology/Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USADepartment of Epidemiology/Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA;Gastrointestinal Oncology Service,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USAGastrointestinal Oncology Service,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USAGastrointestinal Oncology Service,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA;Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USAThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USAThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA

关键词: Bevacizumab;    chemoradiation;    chemotherapy;    radiation;    esophageal cancer;    adenocarcinoma;   

DOI  :  10.21037/jgo.2016.08.09

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown